GC Cell Corporation (144510) · Other

LigaChem Biosciences Inc (141080) · Other

Presentation of preclinical results for two next-generation BCMA ADC pipeline candidates at the American Association for Cancer Research (AACR) 2026 annual meeting scheduled

4/17/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Other

The 16th annual general shareholders' meeting is scheduled for March 31, 2026. Key agenda items include the appointment of directors, with potential for a proxy fight amid a renewed management dispute between major shareholders and current management. High impact is estimated as management disputes often lead to significant price volatility scheduled

3/31/2026, 12:00:00 AM

LigaChem Biosciences Inc (141080) · Other

The 20th Annual General Meeting of Shareholders including approval of financial statements and appointment of a new director scheduled

3/31/2026, 12:00:00 AM

OliX Pharmaceuticals Inc (226950) · Other

Announcement of positive preclinical results for obesity treatment OLX501A showing 84% ALK7 gene suppression in primates and plans to accelerate development expected. High efficacy in primate studies is estimated to result in a price impact of over 5%, expected.

3/24/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Other

Approval from the Ministry of Food and Drug Safety to add 'back pain' as an indication for the NSAID combination drug 'Naxozol' is expected on March 24, 2026. Low impact is estimated as this is an incremental update to an existing product scheduled

3/24/2026, 12:00:00 AM

D&D Pharmatech Inc (347850) · Other

Three key US-based co-founders exercised their stock options on 2026-03-24, signaling strong confidence in the company's long-term growth prospects; low impact estimated as a positive internal signal.

3/24/2026, 12:00:00 AM